According to Zacks, “Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts. “
Several other analysts have also recently commented on BLUE. Jefferies Group reiterated a buy rating and set a $80.00 price target on shares of Bluebird Bio in a research report on Friday, September 23rd. Maxim Group set a $85.00 price target on Bluebird Bio and gave the stock a buy rating in a research report on Thursday, September 22nd. Cowen and Company reiterated an outperform rating on shares of Bluebird Bio in a research report on Friday, September 9th. Vetr cut Bluebird Bio from a buy rating to a hold rating and set a $44.44 price target for the company. in a research report on Monday, July 4th. Finally, Wedbush reiterated an outperform rating and set a $117.00 price target on shares of Bluebird Bio in a research report on Monday, October 3rd. One research analyst has rated the stock with a sell rating, four have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of Buy and a consensus price target of $90.25.
Bluebird Bio (NASDAQ:BLUE) opened at 69.67 on Wednesday. The stock’s market capitalization is $2.59 billion. The company has a 50 day moving average of $61.78 and a 200-day moving average of $50.12. Bluebird Bio has a 12-month low of $35.37 and a 12-month high of $99.70.
Bluebird Bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, August 3rd. The company reported ($1.59) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.44) by $0.15. The business had revenue of $1.55 million for the quarter, compared to analyst estimates of $2.01 million. Bluebird Bio had a negative return on equity of 24.85% and a negative net margin of 3,512.13%. The company’s quarterly revenue was down 68.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.57) earnings per share. On average, equities research analysts forecast that Bluebird Bio will post ($6.19) earnings per share for the current year.
In other Bluebird Bio news, insider Eric Sullivan sold 416 shares of the stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $67.00, for a total value of $27,872.00. Following the sale, the insider now owns 5,891 shares of the company’s stock, valued at approximately $394,697. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David Davidson sold 1,000 shares of the stock in a transaction dated Friday, July 15th. The shares were sold at an average price of $45.08, for a total value of $45,080.00. Following the completion of the sale, the insider now directly owns 10,600 shares in the company, valued at approximately $477,848. The disclosure for this sale can be found here. Corporate insiders own 3.50% of the company’s stock.
A number of large investors have recently bought and sold shares of the stock. Wellington Management Group LLP bought a new stake in Bluebird Bio during the first quarter worth about $51,095,000. BlackRock Inc. raised its stake in Bluebird Bio by 341.0% in the first quarter. BlackRock Inc. now owns 4,569 shares of the company’s stock worth $194,000 after buying an additional 3,533 shares in the last quarter. California State Teachers Retirement System raised its stake in Bluebird Bio by 2.2% in the second quarter. California State Teachers Retirement System now owns 77,687 shares of the company’s stock worth $3,363,000 after buying an additional 1,682 shares in the last quarter. Swiss National Bank raised its stake in Bluebird Bio by 10.6% in the second quarter. Swiss National Bank now owns 59,707 shares of the company’s stock worth $2,585,000 after buying an additional 5,700 shares in the last quarter. Finally, Iguana Healthcare Management LLC bought a new stake in Bluebird Bio during the first quarter worth about $1,030,000.
About Bluebird Bio
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.